Healthcare Equipment and Supplies
Company Overview of Sanovas, Inc.
Sanovas, Inc. provides medical devices for the treatment of lung cancer. It offers its solutions based on vas zeppelin clear vessel technology for drug therapy, physiologic metrics, micro biopsy, and immuno-therapy applications. The company also provides MicroCam, an OEM plug and play micro imaging platform for endoscopic device applications. Its MicroCam technology features proprietary software, electronics, sensors, and optics that provide autonomous imaging capability when integrated with medical device makers' existing portfolios. Sanovas was incorporated in 2010 and is based in Sausalito, California.
85 Liberty Ship Way
Sausalito, CA 94965
Founded in 2010
Key Executives for Sanovas, Inc.
Co-Founder, Chief Executive Officer and President
Vice President of Business Development
Vice President of Clinical Affairs and Physician Education
Compensation as of Fiscal Year 2015.
Sanovas, Inc. Key Developments
Sanovas, Inc. Receives FDA Clearance for Pulmovia
Jun 12 15
Sanovas, Inc. announced that the company has received FDA 510(k) Clearance to market its PulmoVia Working Channel. The PulmoVia is one of several essential tools in the platform of patented technologies Sanovas is developing to improve diagnostic and therapeutic interventions in the lung. Traditional Bronchoscopes incorporate small-diameter operating channels into large-diameter optical assemblies. This combination of devices has limited the size, quantity and capabilities of the tools the clinician can effectively pass through these small diameter operating channels to diagnose and treat the lungs. The large optical and steering components of Traditional Bronchoscopes compromise the available size left for the working channel, thus restricting the size of complementary endoscopic accessories, such as Biopsy forceps, that may be passed through them. These traditionally small channels also restrict flow, hampering attempts to irrigate and suction the lungs of critical care patients with heavy bronchial secretions and clots. The PulmoVia decouples the operating channel from the optical assembly to transform the current paradigm, thereby enabling the delivery of a large-diameter operating channel via a small-diameter optic. This advance can effectively double the amount of space within the operating channel, without increasing the geometric footprint of the device. This naturally maximizes the size, quantity and capabilities of the tools the clinician can use to diagnose and treat the lungs. The PulmoVia Working Channel was designed so that clinicians can utilize much larger instruments to obtain tissue samples, retrieve foreign bodies, and initiate therapies while keeping their critical care patients breathing easily. In addition, since PulmoVia is a single-patient-use, disposable device procedure costs are minimized while staff is freed from the burdens of reprocessing.
Sanovas, Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015
Apr 6 15
Sanovas, Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015 . Venue: Caesars Palace, Las Vegas, Nevada, United States.
Sanovas, Inc. Expands Management Team
Apr 28 14
Sanovas Inc. announced that it has appointed five experienced executives to its management team: Ray Gamini (Sun Microsystems, Cisco Systems), Vice President of Finance; Roy Morgan (Abbott Laboratories, NIPRO Diabetes Systems, Stryker), Director, Research & Development; Christian Haller (MPR Associates), Vice President, Business Development; Steve Budill (Merit Medical, Stryker), Vice President, Product Management; and, John Galasso (Abbott Laboratories, Ascend/Lucent Technologies), Manager, Mechanical Engineering.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 12, 2015